

Partner, New York

Finance



T: 212.735.3682
janine.jjingo@skadden.com

Education

J.D., Columbia University
School of Law, 2005

B.A., University of Pennsylvania, 2002
(*magna cum laude*)

Bar Admissions

New York

M. Janine Jjingo is head of the Finance Group in Skadden's New York office. She is a corporate and finance attorney, primarily representing public and private corporations, as well as investment banks, commercial banks, private equity funds and financial institution investors in a wide range of U.S. and cross-border transactions. Ms. Jjingo frequently advises on secured and unsecured financings, acquisition financings, asset-backed loans, restructuring and debtor-in-possession financings, and other types of complex and traditional financings.

Ms. Jjingo regularly counsels a variety of financial institutions, including Bank of America, Barclays, Citibank, Credit Suisse, HSBC, ING and Morgan Stanley. Additionally, she counsels clients on a range of ESG-related matters.

Ms. Jjingo has been repeatedly named one of *Lawdragon's* 500 Leading Lawyers in America and 500 Leading Dealmakers in America. Additionally, she has been recognized in *The Best Lawyers in America*, as a Rising Star in *IFLR1000* and a Rising Star Best in Banking & Finance at *Euromoney Legal Media Group's* Americas Rising Star Awards.

Her representations have included:

- Adtalem Global Education Inc. in a new credit agreement that provided for \$850 million of senior secured term B loans and a \$400 million of revolving credit facility to finance its acquisition of Walden e-Learning, LLC from Laureate Education, Inc.
- Bank of America, N.A. as administrative agent in the extension of TreeHouse Foods, Inc.'s existing credit agreement, which provided for the amendment and extension of their existing \$750 million revolving credit facility and \$500 million term loan A facility, and an increase in the Tranche A-1 term loans from \$900 million to \$930 million
- Strongbridge Biopharma plc in its \$267 million acquisition by Xeris Pharmaceuticals, Inc.
- NextEra Energy Resources, LLC, a subsidiary of NextEra Energy, Inc., in two transactions for \$1.3 billion in total proceeds, which provided for its sale of a 90% interest in a 1,000-megawatt portfolio of long-term contracted wind and solar generation facilities and a 100% interest in a 100-MW solar-plus-storage project
- NextEra Energy Partners, LP in:
 - connection with its entry into a convertible equity portfolio financing arrangement with a fund managed by BlackRock Global Energy & Power Infrastructure
 - its \$1.02 billion acquisition of a portfolio of 10 wind and solar projects, collectively consisting of 1,192 megawatts. In conjunction with the acquisition, NextEra Energy Partners also entered into a US\$900 million convertible equity portfolio financing with a fund managed by Kohlberg Kravis Roberts & Co. L.P. This transaction was named Americas Power Deal of the Year by *Project Finance International* and Renewables Deal of the Year by *Power Finance & Risk*
- Visteon Corporation in various amendments to its credit agreement including the replacement and repricing of the existing term facility with a new \$350 million term loan facility; and in the \$3.6 billion sale of its 70% stake in Halla Visteon Climate Control Corp. (South Korea)
- Key Safety Systems, Inc. in its \$1.6 billion acquisition of substantially all of the assets and operations of Takata Corporation (Japan), as part of Takata's Chapter 11 case

M. Janine Jjingo

Continued

-
- BlackRock, Inc. in a variety of matters involving revolving credit facilities and its \$20 billion acquisition of Barclays Global Investors
 - Synergy Pharmaceuticals in its Chapter 11 filing, DIP financing and sale of substantially all of its assets to Bausch Health
 - Pinnacle Entertainment, Inc. in its \$2.8 billion acquisition by Penn National Gaming, Inc.
 - DST Systems, Inc. in its \$5.4 billion acquisition by SS&C Technologies Holdings, Inc.
 - Permira Funds in connection with a first-lien \$325 million term loan and \$50 million revolving facility, in addition to a second-lien \$120 million term loan to finance its acquisition of DiversiTech Holdings, Inc.
 - Gilead in a variety of matters, including its \$11.9 billion acquisition of Kite Pharma, Inc. and its \$11 billion acquisition of Pharmasset, Inc.
 - Valeant Pharmaceuticals International, Inc. in its:
 - \$2.6 billion acquisition of Medicis Pharmaceutical Corporation
 - \$800 million acquisition of Mercury (Cayman) Holdings, the holding company of Amoun Pharmaceutical Company S.A.E. (Egypt)
 - its \$15 billion acquisition of Salix Pharmaceuticals Ltd.
 - A&E Television Networks in connection with the financing of NBCUniversal Media, LLC's \$3 billion sale of its 15.8% stake in A&E to The Walt Disney Corporation and Hearst Corporation
 - E.I. DuPont de Nemours and Company in its:
 - \$7.4 billion acquisition of Danisco A/S, a manufacturer of food ingredients
 - in a \$3.5 billion revolving credit facility from JPMorgan Chase Bank, N.A.